文献速递流行病学与生物统计医学教育与科研方法

评估临床试验多样性的框架

A framework for evaluating the diversity of clinical trials.
PubMed 文献 · J Clin Epidemiol · 2024-02-22

本文介绍临床试验多样性评级(CDR)框架及其四步开发过程,包括范围综述、横断面研究、工具创建和咨询小组反馈整合。范围综述纳入110篇文献,发现种族/民族、性别和年龄是最常评估的特征,约85%明确基准但仅48%使用疾病患病率作为基准。CDR框架为评估临床试验多样性提供客观透明的方法。

要点

  • CDR框架经范围综述、横断面研究、工具创建和咨询小组反馈四步开发。
  • 范围综述纳入110篇文献,种族/民族、性别和年龄最常被评估。
  • 约85%文献明确评估基准,但仅48%使用疾病患病率作为基准。

核心结论

  • CDR框架为评估临床试验多样性提供客观透明的方法,可供卫生技术评估机构、临床试验监管机构、政策制定者、期刊编辑和研究人员使用。

研究设计与样本

  • 框架开发为四步过程:范围综述、横断面研究、工具创建、整合咨询小组反馈。
  • 范围综述识别了110篇评估临床试验多样性的出版物。

主要发现

  • 范围综述中种族/民族、性别和年龄是最常评估的特征。
  • 约85%的出版物明确界定了评估所用基准,但不到一半(48%)使用疾病患病率作为基准。
  • 仅64%的研究界定了何为充分代表性。
  • 横断面研究应用了文献中识别的一些方法,帮助识别评估跨国试验和某些人口学特征的复杂性。

关键数值与推荐

  • CDR框架的关键决策包括评估的人口学特征、评估基准和阈值,以及这些因素如何贡献于临床试验多样性的总体评级。
  • 关键决策由前两个阶段和咨询小组反馈提供信息。

临床怎么用

  • 卫生技术评估机构、临床试验监管机构、政策制定者、期刊编辑和个体研究人员可使用该工具检查、监测和改善临床试验多样性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The topic of diversity in clinical trials is rising to the forefront of many conversations in evidence-based medicine, and efforts are being made to improve the diversity of clinical trials. However, there is little uniformity in the methods used to evaluate these efforts. In this article, we describe our Clinical trial Diversity Rating (CDR) framework and the development process, including the broader considerations for evaluating the demographic diversity of clinical trials and their implications, and demonstrate its use through an illustrative example. STUDY DESIGN AND SETTING: The development of the framework was a four-step process, including a scoping review, a cross-sectional study, creation of the tool, and integration of feedback from an advisory group. RESULTS: Our scoping review identified 110 publications that examined clinical trial diversity. Race/ethnicity, sex, and age were the most common characteristics evaluated. About 85% clearly defined the benchmark used for evaluation, but less than half (48%) used disease prevalence as the benchmark. Only 64% of studies defined what would be considered adequate representation. The cross-sectional study, which applied some of the approaches identified in the literature, helped to identify the complexities of evaluating multinational trials and certain demographic characteristics. Key decisions for the CDR framework, such as the demographic characteristics to be evaluated, the benchmark and thresholds for evaluation, and how these factors contribute to the overall rating of clinical trial diversity, were informed by the two earlier phases and feedback from an advisory group. CONCLUSION: The CDR framework provides an objective and transparent approach to evaluating clinical trial diversity. Groups such as Health Technology Assessment bodies, clinical trial regulators, policymakers, journal editors, and individual researchers can use this tool to examine, monitor, and improve diversity in clinical trials.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Agboola F, Wright AC. A framework for evaluating the diversity of clinical trials. J Clin Epidemiol. 2024. PMID: 38395092. doi:10.1016/j.jclinepi.2024.111299

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。